Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation
Introduction: The optimal treatment for recurrent glioblastoma patients remains not well-defined in international guidelines. On top of that, the availability of national guidelines is uncharted. Research question: This study aimed to investigate the availability of national guidelines on the diagno...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Brain and Spine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772529424011792 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846121940297711616 |
|---|---|
| author | Mark P. van Opijnen Rob J.A. Nabuurs Filip Y.F. de Vos Mohini T.R. Ramsoedh Joost J.C. Verhoeff Marjolein Geurts Marike L.D. Broekman |
| author_facet | Mark P. van Opijnen Rob J.A. Nabuurs Filip Y.F. de Vos Mohini T.R. Ramsoedh Joost J.C. Verhoeff Marjolein Geurts Marike L.D. Broekman |
| author_sort | Mark P. van Opijnen |
| collection | DOAJ |
| description | Introduction: The optimal treatment for recurrent glioblastoma patients remains not well-defined in international guidelines. On top of that, the availability of national guidelines is uncharted. Research question: This study aimed to investigate the availability of national guidelines on the diagnosis and treatment of adult glioma throughout Europe, specifically focusing on recurrent glioblastoma. Material and methods: Medical specialists with neuro-oncology expertise from all European countries were asked for the availability of official national guidelines. The primary outcome was whether guidelines provided recommendations on the treatment of recurrent glioblastoma in adults. Secondary outcomes included treatment specific recommendations and the role of clinical trials in the treatment of recurrent glioblastoma. The quality of the guidelines was assessed using the AGREE II instrument. Results: Of the 50 countries in Europe, information on guideline availability was obtained for 38 countries (76%). In twelve countries (24%) national guidelines on the diagnosis and treatment of glioma in adults exist. Focusing on recurrent glioblastoma, nine (18%) of the European countries provided any recommendations on the treatment of recurrent glioblastoma. In four (33%) guidelines it was explicitly stressed that there is currently no standard or evidence-based treatment for these patients. Discussion and conclusion: National guidelines on the treatment of glioblastoma in adults are not uniformly available in Europe. In addition, and in contrast with international guidelines, the national guidelines differ profoundly in their recommendations regarding recurrent glioblastoma. This could contribute to unwanted practice variation. Efforts are needed to not only optimize, but also harmonize treatment for recurrent glioblastoma patients. |
| format | Article |
| id | doaj-art-32d8d3df3e1a44b39d86949a80a62adb |
| institution | Kabale University |
| issn | 2772-5294 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain and Spine |
| spelling | doaj-art-32d8d3df3e1a44b39d86949a80a62adb2024-12-15T06:18:50ZengElsevierBrain and Spine2772-52942024-01-014103923Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variationMark P. van Opijnen0Rob J.A. Nabuurs1Filip Y.F. de Vos2Mohini T.R. Ramsoedh3Joost J.C. Verhoeff4Marjolein Geurts5Marike L.D. Broekman6Department of Neurosurgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands; Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands; Corresponding author. Department of Neurosurgery, Leiden University Medical Center Albinusdreef 2, 2333 ZA, Leiden, the Netherlands.Department of Neurosurgery, Haaglanden Medical Center, Lijnbaan 32, 2512 VA, The Hague, the Netherlands; Department of Neurosurgery, Haga Teaching Hospital, Els Borst-Eilersplein 275, 2545 AA, The Hague, the NetherlandsDepartment of Medical Oncology, Utrecht University Medical Center, Utrecht, the NetherlandsDepartment of Medicine, University of Leiden, Leiden, the NetherlandsDepartment of Radiation Oncology, Amsterdam University Medical Center, Amsterdam, the NetherlandsBrain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the NetherlandsDepartment of Neurosurgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands; Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands; Department of Neurosurgery, Haaglanden Medical Center, Lijnbaan 32, 2512 VA, The Hague, the NetherlandsIntroduction: The optimal treatment for recurrent glioblastoma patients remains not well-defined in international guidelines. On top of that, the availability of national guidelines is uncharted. Research question: This study aimed to investigate the availability of national guidelines on the diagnosis and treatment of adult glioma throughout Europe, specifically focusing on recurrent glioblastoma. Material and methods: Medical specialists with neuro-oncology expertise from all European countries were asked for the availability of official national guidelines. The primary outcome was whether guidelines provided recommendations on the treatment of recurrent glioblastoma in adults. Secondary outcomes included treatment specific recommendations and the role of clinical trials in the treatment of recurrent glioblastoma. The quality of the guidelines was assessed using the AGREE II instrument. Results: Of the 50 countries in Europe, information on guideline availability was obtained for 38 countries (76%). In twelve countries (24%) national guidelines on the diagnosis and treatment of glioma in adults exist. Focusing on recurrent glioblastoma, nine (18%) of the European countries provided any recommendations on the treatment of recurrent glioblastoma. In four (33%) guidelines it was explicitly stressed that there is currently no standard or evidence-based treatment for these patients. Discussion and conclusion: National guidelines on the treatment of glioblastoma in adults are not uniformly available in Europe. In addition, and in contrast with international guidelines, the national guidelines differ profoundly in their recommendations regarding recurrent glioblastoma. This could contribute to unwanted practice variation. Efforts are needed to not only optimize, but also harmonize treatment for recurrent glioblastoma patients.http://www.sciencedirect.com/science/article/pii/S2772529424011792GlioblastomaRecurrenceTreatmentGuidelinePractice variation |
| spellingShingle | Mark P. van Opijnen Rob J.A. Nabuurs Filip Y.F. de Vos Mohini T.R. Ramsoedh Joost J.C. Verhoeff Marjolein Geurts Marike L.D. Broekman Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation Brain and Spine Glioblastoma Recurrence Treatment Guideline Practice variation |
| title | Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation |
| title_full | Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation |
| title_fullStr | Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation |
| title_full_unstemmed | Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation |
| title_short | Recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas: A matter of European practice variation |
| title_sort | recurrent glioblastoma in national guidelines on the diagnosis and treatment of gliomas a matter of european practice variation |
| topic | Glioblastoma Recurrence Treatment Guideline Practice variation |
| url | http://www.sciencedirect.com/science/article/pii/S2772529424011792 |
| work_keys_str_mv | AT markpvanopijnen recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT robjanabuurs recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT filipyfdevos recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT mohinitrramsoedh recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT joostjcverhoeff recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT marjoleingeurts recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation AT marikeldbroekman recurrentglioblastomainnationalguidelinesonthediagnosisandtreatmentofgliomasamatterofeuropeanpracticevariation |